Janssen - Cilag International — Sponsor Intelligence | 193 EU Trials

Filter these 193 trials by condition, phase, country and more.

Open in Search →

193 Registered trials

60 Recruiting

130 Completed trials

25 Countries active

137 Unique IMPs

100% Results reported

Phase III

Phase II

Phase I

Phase I (Other)

Phase III: 78 Phase II/III: 5 Phase II: 33 Phase I/II: 6 Phase IV: 2 Phase I: 28 Phase I (Other): 36 Phase I (FiH): 3 Other: 2

Oversight events:

2 serious breaches 11 temporary halts 5 urgent safety measures 4 unexpected events 5 corrective measures across 16 trials

View oversight register →

100%

130 of 130 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Non-small cell lung cancer 8 Crohn's disease 7 Prostate cancer metastatic 6 Colorectal cancer 5 Myasthenia gravis 3 Plasma cell myeloma 3 Myelodysplastic syndrome 3 Dermatitis atopic 2 Plasma cell myeloma refractory 2 Prostate cancer recurrent 2 Juvenile psoriatic arthritis 2 Neonatal alloimmune thrombocytopenia 2

Top IMPs

GUSELKUMAB 18 AMIVANTAMAB 15 DEXAMETHASONE 13 NIPOCALIMAB 12 DARATUMUMAB 10 BORTEZOMIB 9 DEXAMETHASONE PH. EUR. 8 JNJ-77242113 8 LAZERTINIB 8 CETRELIMAB 7 ERDAFITINIB 7 HUMAN NORMAL IMMUNOGLOBULIN 7

All trials — page 8

193 total

Seamless Phase 2/3 Study of Ibrutinib With Rituximab in Relapsed/Refractory Mantle Cell Lymphoma Ended

2023-503618-64-00 Phase II 3 countries BORTEZOMIB; IBRUTINIB; LENALIDOMIDE; RITUXIMAB
A Clinical Study to Assess the Safety, Tolerability of JNJ-63733657 and to evaluate how fast and to what extent JNJ-63733657 reaches the blo… Ended

2024-513656-15-00 Phase I (Other) 1 country
A Phase 2, Open-Label, Multi-Center, Randomized Study of TAR-200 in Combination with Cetrelimab and Cetrelimab Alone in Participants with Mu… Ended

2023-507189-17-00 Phase II 6 countries CETRELIMAB; GEMCITABINE HYDROCHLORIDE
A Phase 1b Study of the MALT1 Inhibitor JNJ-67856633 and Ibrutinib in Combination in Relapsed or Refractory B cell Non-Hodgkin Lymphoma and … Ended

2024-512689-32-00 Phase I (Other) 2 countries
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study with a Long-Term Extension Treatment Period to Assess the … Ended

2022-501188-42-00 Phase II 5 countries 6-(FLUORO-18F)-3-(1H-PYRROLO[2,3-C]PYRIDIN-1-YL)-5-ISOQUINOLINAMINE; POSDINEMAB
Clinical Study of the Efficacy, Safety and Pharmacokinetics of Ustekinumab as Intravenous Induction Treatment Followed by Subcutaneous Ustek… Ended

2023-504978-38-00 Phase III 4 countries USTEKINUMAB
A Clinical Study of the Efficacy, Safety and Pharmacokinetics of Ustekinumab as Intravenous Induction Treatment Followed by Subcutaneous Ust… Ended

2023-504977-19-00 Phase III 4 countries USTEKINUMAB
A Phase 1b, Open-Label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-64264681 in Combination with JNJ-67856633 in Parti… Ended

2024-512687-66-00 Phase I (Other) 2 countries
A Phase 1, First-in-Human, Dose Escalation Study of the JNJ-75348780 Bispecific Antibody Targeting CD3 and CD22 in Participants with NHL and… Ended

2023-504403-92-00 Phase I 2 countries
A Phase 1, Open-Label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-64264681 in Participants with Non-Hodgkin Lymphoma … Ended

2024-512686-13-00 Phase I (Other) 1 country
Study of JNJ-74856665 in patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome Ended

2024-513918-35-00 Phase I 1 country
A Clinical Study to Investigate the Efficacy and Safety of JNJ-73763989 + Nucleos(t)ide Analog in Participants Co-infected with Hepatitis B … Ended

2023-506763-33-00 Phase II 3 countries DAPLUSIRAN, TOMLIGISIRAN
A Randomized Phase 2 Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Subjects Who Received Bacillus Calmette… Ended

2023-510306-40-00 Phase II 3 countries ERDAFITINIB; GEMCITABINE; MITOMYCIN
A Phase 1 Study of JNJ-70218902, a T Cell Redirecting Agent, in Advanced Stage Solid Tumors Ended

2024-516351-40-00 Phase I 1 country
A Phase 2 Study of Erdafitinib in Subjects with Advanced Solid Tumors and FGFR Gene Alterations Ended

2023-510301-18-00 Phase II 2 countries ERDAFITINIB
A Phase 1, First-in-Human, Open-Label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-67856633, an Inhibitor of MALT1, in… Ended

2024-512734-15-00 Phase I 2 countries
A Phase 3b, Randomized, Double-blind, Parallel Group, Multicenter Study to Evaluate Further Therapeutic Strategies with Guselkumab in Patien… Ended

2023-508424-34-00 Phase III 1 country GUSELKUMAB
A Study of the Efficacy and Safety of Golimumab in Pediatric Participants with Moderately to Severely Active Ulcerative Colitis Ended

2023-507142-83-00 Phase III 3 countries GOLIMUMAB
A Phase 3 Study Comparing Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) with VELCADE, Lenalidomide, and Dexamet… Ended

2023-507312-13-00 Phase III 6 countries BORTEZOMIB; DARATUMUMAB; DEXAMETHASONE; LENALIDOMIDE
A study to investigate the safety, the amount that reaches the bloodstream and the effects on the body of JNJ-64619178 in people with advanc… Ended

2024-515254-24-00 Phase I 1 country
A Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Urothelial Cancer Ended

2023-510296-56-00 Phase III 3 countries DOCETAXEL; ERDAFITINIB; PEMBROLIZUMAB; VINFLUNINE
A clinical study to compare the safety, effectiveness and pharmacokinetics (the way the body absorbs, distributes, and gets rid of a drug) o… Ended

2023-507143-11-00 Phase III 13 countries DARATUMUMAB
A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination with Cyclophosphamide, Bortezomib and Dexametha… Ended

2024-511967-26-00 Phase III 11 countries ANHYDROUS CYCLOPHOSPHAMIDE; BORTEZOMIB; DARATUMUMAB; DEXAMETHASONE
A study to evaluate the effect of multiple doses of carbamazepine and itraconazole on how long JNJ-55308942 stays in the body (pharmacokinet… Ended

2023-504055-27-00 Phase I (Other) 1 country

Showing 169–192 of 193 trials

← All sponsors A–Z